{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T15:22:51Z","timestamp":1786720971586,"version":"build-2736575974"},"reference-count":101,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,1,31]],"date-time":"2021-01-31T00:00:00Z","timestamp":1612051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Our understanding of fatty liver syndromes and their relationship with the metabolic syndrome has improved over recent decades and, paralleling this, we are now at the dawn of the NAFLD (nonalcoholic fatty liver disease) to MAFLD (metabolic-associated fatty liver disease) transition. The pitfalls of NAFLD diagnosis, together with disappointing results in therapeutic trials, and the inconsistencies and risks inherent in a \u201cnegative\u201d definition (such as \u201cnonalcoholic\u201d) as opposed to a \u201cpositive\u201d one (i.e., \u201cmetabolic\u201d) are predicted to facilitate the proposed renaming of NAFLD to MAFLD. However, a premature change of terminology would not necessarily address major unmet needs in this area, and may even become counterproductive. As an aid to selecting more homogeneous cohorts of patients, I propose the LDE (Liver, Determinants, Extra-hepatic) classification system which, in principle, may help to assess the natural course of disease as well as the efficacy of novel drugs in patients with NAFLD\/MAFLD.<\/jats:p>","DOI":"10.3390\/jcm10030492","type":"journal-article","created":{"date-parts":[[2021,1,31]],"date-time":"2021-01-31T04:53:00Z","timestamp":1612068780000},"page":"492","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition?"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-0698","authenticated-orcid":false,"given":"Amedeo","family":"Lonardo","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Azienda Ospedaliero-Universitaria di Modena, 4110 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,31]]},"reference":[{"key":"ref_1","first-page":"485","article-title":"Observations on fatty degeneration of the liver","volume":"1","author":"Addison","year":"1836","journal-title":"Guys Hosp. Rep."},{"key":"ref_2","first-page":"347","article-title":"Fatty infiltration of the liver and the development of cirrhosis in diabetes and chronic alcoholism","volume":"14","author":"Connor","year":"1938","journal-title":"Am. J. Pathol."},{"key":"ref_3","first-page":"67","article-title":"Sulla patogenesi dell\u2019accumulo del grasso nella steatosi epatica","volume":"66","author":"Dianzani","year":"1964","journal-title":"Rass. Med. Sarda"},{"key":"ref_4","first-page":"434","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin. Proc."},{"key":"ref_5","first-page":"283","article-title":"Nonalcoholic fatty liver disease","volume":"8","author":"Schaffner","year":"1986","journal-title":"Prog. Liver Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-med-051215-031109","article-title":"Nonalcoholic steatohepatitis","volume":"68","author":"Suzuki","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/hep.30094","article-title":"Healthcare cost and utilization in nonalcoholic fatty liver disease: Real-World data from a large, U.S. claims database","volume":"68","author":"Allen","year":"2018","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nrgastro.2016.3","article-title":"Management of NAFLD: A stage-based approach","volume":"13","author":"Rinella","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_10","first-page":"S0016-5085(20)30680-6","article-title":"Why do so many NASH trials fail?","volume":"18","author":"Ratziu","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/liv.14478","article-title":"What\u2019s in a name? Renaming \u2018NAFLD\u2019 to \u2018MAFLD\u2019","volume":"40","author":"Fouad","year":"2020","journal-title":"Liver Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"International consensus panel. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/0016-5085(88)90183-7","article-title":"Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury","volume":"95","author":"Diehl","year":"1988","journal-title":"Gastroenterology"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Italian Association for the Study of the Liver (AISF) (2017). AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Dig. Liver Dis., 49, 471\u2013483.","DOI":"10.1016\/j.dld.2017.01.147"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lonardo, A., Leoni, S., Alswat, K.A., and Fouad, Y. (2020). History of nonalcoholic fatty liver disease. Int. J. Mol Sci., 21.","DOI":"10.3390\/ijms21165888"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2016). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.metabol.2017.04.003","article-title":"Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic\/histological parameters in various liver diseases","volume":"72","author":"Ballestri","year":"2017","journal-title":"Metabolism"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/17474124.2019.1621164","article-title":"A critical appraisal of the use of ultrasound in hepatic steatosis","volume":"13","author":"Ballestri","year":"2019","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/17474124.2018.1415756","article-title":"Clinical relevance of liver histopathology and different histological classifications of NASH in adults","volume":"12","author":"Nascimbeni","year":"2018","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Brunt, E.M. (2016). Nonalcoholic fatty liver disease: Pros and cons of histologic systems of evaluation. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17010097"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/hep4.1055","article-title":"Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation","volume":"1","author":"Brunt","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.anndiagpath.2018.09.009","article-title":"Nonalcoholic fatty liver disease (NAFLD): Diagnosis, pitfalls, and staging","volume":"37","author":"Koch","year":"2018","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/CEG.S101440","article-title":"Autoimmune hepatitis: Current challenges and future prospects","volume":"10","author":"Aizawa","year":"2017","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_27","first-page":"9","article-title":"Non alcoholic fatty liver disease and metabolic syndrome","volume":"13","author":"Paschos","year":"2009","journal-title":"Hippokratia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.dld.2014.09.020","article-title":"Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome","volume":"47","author":"Lonardo","year":"2015","journal-title":"Dig. Liver Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jgh.13264","article-title":"Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis","volume":"31","author":"Ballestri","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.arcmed.2011.12.009","article-title":"Human immunodeficiency virus is the major determinant of steatosis and hepatitis C virus of insulin resistance in virus-associated fatty liver disease","volume":"42","author":"Guaraldi","year":"2011","journal-title":"Arch. Med. Res."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Lonardo, A., Mantovani, A., Lugari, S., and Targher, G. (2019). NAFLD in some common endocrine diseases: Prevalence, pathophysiology, and principles of diagnosis and management. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20112841"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/apt.13052","article-title":"Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: A case-control study","volume":"41","author":"Vodkin","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.dld.2018.12.014","article-title":"Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?","volume":"51","author":"Lonardo","year":"2019","journal-title":"Dig. Liver Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1210\/er.2008-0024","article-title":"The metabolic syndrome","volume":"29","author":"Cornier","year":"2008","journal-title":"Endocr. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2217\/dmt.14.30","article-title":"Obesity and metabolic syndrome: The contribution of visceral fat and Adiponectin","volume":"4","author":"Matsuzawa","year":"2014","journal-title":"Diabetes Manag."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10552-017-0869-z","article-title":"IARC working group on energy balance and obesity. Energy balance and obesity: What are the main drivers?","volume":"28","author":"Romieu","year":"2017","journal-title":"Cancer Causes Control"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/MOL.0000000000000276","article-title":"Metabolic syndrome: Genetic insights into disease pathogenesis","volume":"27","author":"Ziki","year":"2016","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_40","first-page":"1","article-title":"Metabolic syndrome and insulin resistance: Underlying causes and modification by exercise training","volume":"3","author":"Roberts","year":"2013","journal-title":"Compr. Physiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jhep.2006.06.011","article-title":"Chicken or egg turned into head or belly","volume":"45","author":"Lonardo","year":"2006","journal-title":"J. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/s41467-020-15686-y","article-title":"Brain insulin sensitivity is linked to adiposity and body fat distribution","volume":"11","author":"Kullmann","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1007\/s00125-006-0280-x","article-title":"Neel revisited: The adipocyte, seasonality and type 2 diabetes","volume":"49","author":"Scott","year":"2006","journal-title":"Diabetologia"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Lonardo, A., and Ballestri, S. (2020). Perspectives of nonalcoholic fatty liver disease research: A personal point of view. Explor. Med., 1.","DOI":"10.37349\/emed.2020.00007"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Binetti, J., Bertran, L., Riesco, D., Aguilar, C., Mart\u00ednez, S., Sabench, F., Porras, J.A., Camaron, J., Del Castillo, D., and Richart, C. (2020). Deregulated serotonin pathway in women with morbid obesity and NAFLD. Life, 10.","DOI":"10.3390\/life10100245"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Soto-Angona, O., Anmella, G., Vald\u00e9s-Florido, M.J., De Uribe-Viloria, N., Carvalho, A.F., Penninx, J.H., and Berk, M. (2020). Non-Alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: Common pathways and future approaches. BMC Med., 18.","DOI":"10.1186\/s12916-020-01713-8"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/met.2008.0070","article-title":"Health care utilization and costs by metabolic syndrome risk factors","volume":"7","author":"Boudreau","year":"2009","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wainwright, P., and Byrne, C.D. (2016). Bidirectional relationships and disconnects between NAFLD and features of the metabolic syndrome. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17030367"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1586\/egh.11.19","article-title":"Insulin resistance in nonalcoholic steatohepatitis: Necessary but not Sufficient\u2014Death of a dogma from analysis of therapeutic studies?","volume":"5","author":"Lonardo","year":"2011","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1055\/s-0032-1306422","article-title":"NAFLD in the absence of metabolic syndrome: Different epidemiology, pathogenetic mechanisms, risk factors for disease progression?","volume":"32","author":"Yilmaz","year":"2012","journal-title":"Semin. Liver Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.30908","article-title":"Lean NAFLD: A distinct entity shaped by differential metabolic adaptation","volume":"71","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Lonardo, A., and Suzuki, A. (2020). Sexual dimorphism of NAFLD in adults. focus on clinical aspects and implications for practice and translational research. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051278"},{"key":"ref_53","first-page":"83","article-title":"Sex disparity in hepatocellular carcinoma owing to NAFLD and non-NAFLD etiology. Epidemiological findings and patho-mechanisms","volume":"6","author":"Lonardo","year":"2020","journal-title":"Hepatoma Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1373\/clinchem.2013.202549","article-title":"Sex differences in the metabolic syndrome: Implications for cardiovascular health in women","volume":"60","author":"Pradhan","year":"2014","journal-title":"Clin. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)31561-0","article-title":"Sex and gender: Modifiers of health, disease, and medicine","volume":"396","author":"Merz","year":"2020","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2468-1253(17)30146-2","article-title":"Is it time to change NAFLD and NASH nomenclature?","volume":"2","author":"Bellentani","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"GS-US-321-0105 and GS-US-321-0106 investigators. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jhep.2019.11.024","article-title":"A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis","volume":"72","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study","volume":"72","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jhep.2019.04.019","article-title":"Participants of the AASLD\/EASL workshop. Report on the AASLD\/EASL joint workshop on clinical trial endpoints in NAFLD","volume":"71","author":"Rinella","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2468-1253(20)30340-X","article-title":"The Latin American association for the study of the liver (ALEH) position statement on the redefinition of fatty liver disease","volume":"6","author":"Arrese","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S2468-1253(20)30213-2","article-title":"Nomenclature and definition of metabolic-associated fatty liver disease: A consensus from the Middle East and north Africa","volume":"6","author":"Shiha","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients with Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study","volume":"155","author":"Castellanos","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.3748\/wjg.v23.i36.6571","article-title":"Nonalcoholic fatty liver disease: Evolving paradigms","volume":"23","author":"Lonardo","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"154413","DOI":"10.1016\/j.metabol.2020.154413","article-title":"Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name","volume":"113","author":"Polyzos","year":"2020","journal-title":"Metabolism"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/hep.26072","article-title":"Hepatic fat loss in advanced nonalcoholic steatohepatitis: Are alterations in serum adiponectin the cause?","volume":"57","author":"Samer","year":"2013","journal-title":"Hepatology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/hep.510290347","article-title":"Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease","volume":"29","author":"Caldwell","year":"1999","journal-title":"Hepatology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1111\/j.1572-0241.2006.00719.x","article-title":"Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD","volume":"101","author":"Kang","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"ref_70","first-page":"9","article-title":"High prevalence of advanced fibrosis in association with the metabolic syndrome in a Belgian prospective cohort of NAFLD patients with elevated ALT. Results of the Belgian NAFLD registry","volume":"74","author":"Francque","year":"2011","journal-title":"Acta Gastroenterol. Belg."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/liv.14362","article-title":"Natural history of NASH and HCC","volume":"40","author":"Negro","year":"2020","journal-title":"Liver Int."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e0214","DOI":"10.1097\/MD.0000000000010214","article-title":"Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)","volume":"97","author":"Golabi","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: Disentangling microbial signatures from metabolic disorders","volume":"17","author":"Vigliotti","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2006.09.018","article-title":"NAFLD and hyperinsulinemia are major determinants of serum ferritin levels","volume":"46","author":"Halpern","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2007.01.004","article-title":"Ferritin, metabolic syndrome and NAFLD: Elective attractions and dangerous liaisons","volume":"46","author":"Trombini","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41575-019-0212-0","article-title":"Genetic contributions to NAFLD: Leveraging shared genetics to uncover systems biology","volume":"17","author":"Eslam","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Pu, K., Wang, Y., Bai, S., Wei, H., Zhou, Y., Fan, J., and Qiao, L. (2019). Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: A systematic review and meta-analysis. BMC Gastroenterol., 19.","DOI":"10.1186\/s12876-019-0961-9"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/17474124.2019.1608820","article-title":"Noninvasive monitoring of hepatic steatosis: Controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease","volume":"13","author":"Lee","year":"2019","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/17512433.2017.1299573","article-title":"Magnetic resonance imaging and transient elastography in the management of nonalcoholic fatty liver disease (NAFLD)","volume":"10","author":"Han","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH-current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Ballestri, S., Mantovani, A., Baldelli, E., Lugari, S., Maurantonio, M., Nascimbeni, F., Marrazzo, A., Romagnoli, D., Targher, G., and Lonardo, A. (2021). Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease. Diagnostics, 11.","DOI":"10.3390\/diagnostics11010098"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1097\/QAI.0000000000001936","article-title":"Diagnostic accuracy of noninvasive markers of steatosis, NASH, and liver fibrosis in HIV-monoinfected individuals at risk of nonalcoholic fatty liver disease (NAFLD): Results from the ECHAM study","volume":"80","author":"Lemoine","year":"2019","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/hep.30672","article-title":"Liver forum case definitions working group. Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: Recommendations from the liver forum","volume":"70","author":"Cheung","year":"2019","journal-title":"Hepatology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/jhep.2003.50229","article-title":"Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values","volume":"37","author":"Mofrad","year":"2003","journal-title":"Hepatology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cgh.2020.04.067","article-title":"Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: A systematic review and meta-analysis","volume":"19","author":"Balakrishnan","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jhep.2005.06.018","article-title":"Hepatic steatosis and insulin resistance: Does etiology make a difference?","volume":"44","author":"Lonardo","year":"2006","journal-title":"J. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.atherosclerosis.2016.12.018","article-title":"Non-Alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically-versus genetically-driven excess fat hepatic storage","volume":"257","author":"Polimeni","year":"2017","journal-title":"Atherosclerosis"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/00365513.2019.1700428","article-title":"Metabolic syndrome but not genetic polymorphisms known to induce NAFLD predicts increased total mortality in subjects with NAFLD (OPERA study)","volume":"80","author":"Hukkanen","year":"2020","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ajg.2013.476","article-title":"The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: A meta-analysis","volume":"109","author":"Singal","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1038\/s41598-017-04991-0","article-title":"MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals","volume":"7","author":"Donati","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/tpj.2017.45","article-title":"The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro","volume":"18","author":"Pillai","year":"2018","journal-title":"Pharmacogenom. J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s12020-020-02470-7","article-title":"PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide","volume":"70","author":"Chen","year":"2020","journal-title":"Endocrine"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","article-title":"Update on NAFLD genetics: From new variants to the clinic","volume":"72","author":"Valenti","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.4155\/fmc-2019-0003","article-title":"Extra-Hepatic manifestations and complications of nonalcoholic fatty liver disease","volume":"11","author":"Ballestri","year":"2019","journal-title":"Future Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Rosato, V., Masarone, M., Dallio, M., Federico, A., Aglitti, A., and Persico, M. (2019). NAFLD and extra-hepatic comorbidities: Current evidence on a multi-organ metabolic syndrome. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16183415"},{"key":"ref_96","first-page":"472","article-title":"Extrahepatic complications of non-alcoholic fatty liver disease: Its impact beyond the liver","volume":"84","author":"Velasco","year":"2019","journal-title":"Rev. Gastroenterol. Mex."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cld.2015.10.004","article-title":"Extrahepatic complications of nonalcoholic fatty liver disease","volume":"20","author":"Chacko","year":"2016","journal-title":"Clin. Liver Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0035-1562944","article-title":"Systemic complications of nonalcoholic fatty liver disease: When the liver is not an innocent bystander","volume":"35","author":"Vanni","year":"2015","journal-title":"Semin. Liver Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jhep.2018.07.020","article-title":"A changing landscape of liver transplantation: King HCV is dethroned, ALD and NAFLD take over!","volume":"69","author":"Terrault","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Younossi, Z.M., Rinella, M.E., Sanyal, A., Harrison, S.A., Brunt, E., Goodman, Z., Cohen, D.E., and Loomba, R. (2020). From NAFLD to MAFLD: Implications of a premature change in terminology. Hepatology.","DOI":"10.1002\/hep.31420"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14548","article-title":"Comparison of MAFLD and NAFLD diagnostic criteria in real world","volume":"40","author":"Lin","year":"2020","journal-title":"Liver Int."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/3\/492\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:17:49Z","timestamp":1760159869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/3\/492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,31]]},"references-count":101,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["jcm10030492"],"URL":"https:\/\/doi.org\/10.3390\/jcm10030492","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,31]]}}}